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Abstract
Background: ATRX is a severe X-linked disorder characterized by mental retardation, facial dysmorphism,
urogenital abnormalities and alpha-thalassemia. The disease is caused by mutations in ATRX gene, which encodes
a protein belonging to the SWI/SNF DNA helicase family, a group of proteins involved in the regulation of gene
transcription at the chromatin level. In order to identify specific genes involved in the pathogenesis of the disease,
we compared, by cDNA microarray, the expression levels of approximately 8500 transcripts between ATRX and
normal males of comparable age.
Methods: cDNA microarray was performed using total RNA from peripheral blood mononuclear cells of ATRX and
normal males. Microarray results were validated by quantitative real-time polymerase chain reaction.
Results: cDNA microarray analysis showed that 35 genes had a lower expression (30-35% of controls) while 25
transcripts had a two-fold higher expression in comparison to controls. In the microarray results the probe for
oligophrenin-1, a gene known for its involvement in mental retardation, showed a decreased hybridization signal.
However, such gene was poorly expressed in blood mononuclear cells and its decrease was not confirmed in the
quantitative real-time RT-PCR assay. On the other hand, the expression of an homologous gene, the GTPase
regulator associated with the focal adhesion kinase 1/Oligophrenin-1-like (GRAF1/OPHN-1-L), was relatively high in
blood mononuclear cells and significantly decreased in ATRX patients. The analysis of the expression pattern of the
GRAF1/OPHN-1-L gene in human tissues and organs revealed the predominant brain expression of a novel splicing
isoform, called variant-3.
Conclusions: Our data support the hypothesis of a primary role for altered gene expression in ATRX syndrome
and suggest that the GRAF1/OPHN-1-L gene might be involved in the pathogenesis of the mental retardation.
Moreover a novel alternative splicing transcript of such gene, predominantly expressed in brain tissues, was
identified.
Background
The XNP/ATRX gene encodes a 2492 amino acid chro-
matin-associated protein which bears, at the N-termi-
nus, a region (encoded by exons 8-10) named ATRX-
DNMT3-DNMT3L (ADD) domain and containing a N-
terminal GATA-like zinc finger, a plant homeodomain
finger and a long C-terminal that pack together to form
a single globular domain [1,2]. At the C-terminus is
present a helicase/ATP domain (encoded by exons 18-
31) formed by seven conserved “helicase” motifs found
in DNA-stimulated ATPases and DNA helicases of the
SNF2/SWI2 protein family [3-6]. SWI/SNF [Switching
defective (SWI) and Sucrose nonfermenting) (SNF)]
complexes function as global gene regulators, altering
the chromatin structure and changing the accessibility
of transcription factor to DNA in a subset of specific
genes [7].
Mutations in the XNP/ATRX gene, located in Xq13.3,
are associated with × linked mental retardation
* Correspondence: condorda@unict.it
1Laboratorio sui Sistemi Complessi, Scuola Superiore di Catania, University of
Catania, Catania, Italy
Barresi et al. BMC Medical Genomics 2010, 3:28
http://www.biomedcentral.com/1755-8794/3/28
© 2010 Barresi et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.syndromes, the best known being alpha thalassaemia
with mental retardation (ATRX, MIM 301040)
[3,4,8-12]. Previous studies have shown that ATRX
mutations are predominantly found within the zinc-fin-
ger or the helicase domain and result in comparable
clinical manifestations[11,12].
Several lines of evidence suggest that XNP/ATRX is
involved in gene expression regulation via chromatin
remodelling through the following mechanisms: 1) its
association with the human EZH2 protein [5,13], a
human homologue of the Enhancer of Zeste Drosophila
gene involved in the regulation of homeotic gene
expression through chromatin remodelling; 2) its inter-
action with the heterochromatin protein HP1 [14]; 3)
the abnormalities of DNA methylation profiles of repeti-
tive elements induced by ATRX mutations [12]; 4) the
nuclear localization and the close association with peri-
centromeric heterochromatin during mitosis [13,15]; 5)
the documented DNA-binding activity of the zinc finger
domain [6]; 6) the co-localization with the transcription
co-activator Daxx in promyelocytic leukaemia nuclear
bodies [16].
To date the cellular mechanism(s) underlying the
ATRX syndrome remain unknown. Despite the rarity of
this syndrome the identification of involved genes can
s u p p l yu s e f u ld a t af o rt h eg e n eral understanding of the
molecular mechanisms responsible for mental
retardation.
In the present work we have applied the cDNA micro-
rray technique as an exploratory preliminary tool with
the intent to identify alterations of gene expression that
might provide useful hints to the pathogenetic mechan-
ism of the ATRX syndrome. Validation of microarray
results was performed by quantitative real-time poly-
merase chain reaction (qRT-PCR analysis). Although the
analysis was performed on peripheral blood cells, signifi-
cant changes in the expression profile were revealed.
Moreover, GTPase regulator associated with the focal
adhesion kinase 1/Oligophrenin-1-like (GRAF1/OPHN-
1-L), one of the gene showing altered expression level in
ATRX, is potentially involved in Central Nervous Sys-
tem (CNS) function and in mental retardation and we
report the identification of a novel alternative transcript
and its tissue and brain distribution.
Methods
Clinical findings and ATRX gene mutations
Three male patients, ATRX-1 (age 12 years), ATRX-2
(age 12 years) and ATRX-3 (age 14 yrs), presenting
peculiar features of the ATRX syndrome, were analysed
in the present study after informed consent by parents
or ligal guardians. All patients showed a profound men-
tal retardation, microcephaly, facial dysmorphisms, and
short stature (all below the 3
rd centile). Clinical findings
and ATRX gene mutations of each patient were pre-
viously described [9,17].
Peripheral blood mononuclear cell isolation
Peripheral blood mononuclear (PBM) cells were isolated
f r o m5m lo fE D T A( K 3)[ K 3E] blood by Ficoll gradient
procedure. The whole blood was diluted with Hanks’s
solution (volume ratio 1:1) (Life Technologies, Paisley,
Scotland) and was added to tube with Ficoll Separating
Solution (volume ratio 1:1) (BIOCHROM KG, Berlin).
After centrifugation for 35 min a 400 g, the mononuc-
lear cells containing layer was carefully pipetted away
and resuspended in Phosphate Buffer Saline (PBS, pH
7.4). The cellular pellet was washed in PBS solution two
times.
RNA extraction and cDNA synthesis
Total RNA was extracted as described by Chomczynski
and Sacchi [18]. The quantity and purity of RNA were
confirmed by spectrophotometry and agarose gel elec-
trophoresis. Reverse transcription was performed using
total RNA, RNase H
- reverse transcriptase (Superscript
II, Gibco BRL, Life Technologies, Gaithersburg, MD)
and random primer hexamers.
cDNA microarray
cDNA microarray data was obtained using a Human
UniGene 1 Microarray (IncyteGenomics, St. Louis, Mis-
souri, USA) that contains a set of 9128 clones corre-
sponding to 8524 unique genes/EST clusters. The
analysis has been performed on pooled RNA extracted
by PBMC pellet of three ATRX patients in comparison
to that obtained from a pool of 42 normal males (7.6 ±
2.4 years). The results were analyzed with the GEM-
TOOLS Analysis Software (Incyte Genomics). Raw and
processed cDNA microarray data have been submitted
to public repository: “Gene Expression Omnibus-GEO”
http://www.ncbi.nlm.nih.gov/geo with the accession
number GSE22028.
Separation of reticulocytes and immortalized
lymphoblasts of control and pathological subjects
Approximately 10 ml peripheral blood in heparin were
obtained from controls and patients. Peripheral blood
samples were washed 3 times in reticulocyte saline buf-
fer (4°C) (RS: 1.3 M NaCl, 0.05 M KCl, 0.074 M
MgCl2.6H2O pH 7.4) and then centrifuged at 10000 g
for 20 minutes at 4°C and 0.5 ml was removed from the
reticulocyte-rich top layer. Reticulocytes were concen-
trated by centrifugation at 3500 rpm for 30 min at 4°C.
The supernatant was removed, and the top 0.3-0.5 ml
reticulocyte-rich fraction was added to 2 ml of ice-cold
RS and layered on a column consisting of 10 ml of 2
parts cellulose (C-8002, Sigma-Aldrich, Steinheim,
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cellulose (S-5504, Sigma-Aldrich, Steinheim, Germany)
in RS. The red cells were eluted by centrifuging the col-
umn at 1200 rpm at 4°C for 2 min. The eluate was
washed three times in 10 ml of ice-cold PBS and then
the reticulocyte enriched fraction was recovered by cen-
trifugation and resuspended in 2 ml of ice-cold PBS.
RNA was extracted with TRI reagent (T-9424, Sigma-
Aldrich, Steinheim, Germany). Lymphoblasts from EBV
cell lines of controls (Immort CTRLs) and patients
(Immort ATRX-1 and ATRX-2) were maintained in
RPMI-1640 (Gibco, Invitrogen, Scotland, UK) media
supplemented with 10% (vol/vol) heat-inactivated fetal
bovine serum and penicillin-streptomycin (50 units/50
μg/ml). The cell cultures were incubated at 37°C in a
humidified 5% CO2 incubator and the culture medium
was changed twice a week.
Human brain tissues and non cerebral RNAs
Brain tissue from five human subjects were studied: four
males (ages 18, 26, 46, and 61) and one female (age 22)
with postmortem interval between 4 and 36 hours. The
specimens had been obtained at autopsy from the For-
ensic Medicine Department at the Karolinska Institute
under guidelines approved by the ethics committee and
the Swedish Board of Health and Social Welfare. The
specimens were frozen in dry ice-cooled isopentane and
stored at -80°C. We have only access to blocks of tissue
from selected areas (spinal cord, medulla oblongata, cer-
ebellum, striatum, hippocampus and neocortex). Total
RNA was extracted as described by Chomczynski and
Sacchi [18].
The human non cerebral total RNAs were commer-
cially obtained from Ambion.Inc (Austin, TX): pancreas
(cod.7954); liver (cod.7960); heart (cod.7966); lung
(cod.7968); spleen (cod.7970); testis (cod.7972); ovary
gland (cod.7974); kidney (cod.7976); skeletel muscle
(cod.7982).
mRNA splice variants by PCR analysis
To detect GRAF1/OPHN-1-L alternative transcripts
were used the following primers: F19: CCGA-
TATGCCTCTCACCAAT; F18: GCAGCCATCATGGA-
CATCAA; R22: AGACCGTGCCTGCTGTGAAC; R22b:
CATTATCGAAGACCGTGCCTG. Amplification were
performed under the following conditions: denaturation
step at 95°C for 3 min; 95°C × 1 min, 67°C for F19-R22
or 60°C for F18-R22b × 2 min, 72°C × 3 min × 35
cycles. Amplification products were separated by 1,8%
agarose gel electrophoresis and visualized with ethidium
bromide. To confirm the identify of alternative amplified
variants, DNA fragments were recovered by glass-milk
method [19] and sequencing was performed by standard
fluorescent dideoxy chain-termination procedure with
the Abi Prism 377 automatic sequencer.
Quantitative Real Time RT-PCR
Quantitative Real Time RT-PCR (qRT-PCR) experi-
ments were performed in the ABI PRISM 7700
Sequence Detection System from Applied Biosystems.
Three sequence-specific oligonucleotides were designed
using the Primer Express oligo design software (Applied
Biosystems) based on the sequence of target gene. The
following genes were analyzed: human Oligophrenin-1
(OPHN-1, GenBank ID: NM_002547, clone ID:
4216520), transcriptional regulator ATRX isoform-1
(XNP/ATRX, GenBank ID: NM_000489), GRAF1/Oligo-
phrenin-1-like (GRAF1/OPHN-1-L, GenBank ID:
NM_015071), Alpha hemoglobin (GenBank ID:
NM_000558), Beta hemoglobin (GenBank ID:
NM_000518), HAIK1 type I, intermediate filament cyto-
cheratin or human Keratin 23 gene (HAIK1 or KRT23,
c l o n eI D :2 8 2 0 3 7 2 ) ,p u t a t i v el y m p h o c y t eG 0 / G 1s w i t c h
or G0S2 gene (G0/G1 or G0S2, GenBank ID: BE873759,
clone ID 1217764).
Primers and probes used for qRT-PCR are reported in
Additional file 1 Table S1. Details of the conditions
used for qRT-PCR are previously described [20].
Results
Identification of the genes whose expression is altered in
ATRX peripheral blood cells
cDNA microarray results showed that only a limited
number of genes was significantly affected in the ATRX
syndrome. Out of 8524 transcripts analyzed 35
decreased (ratio ATRX/control < 0.5; Table 1) while 25
increased (ratio ATRX/control > 2; Table 2).
In order to confirm the results obtained by cDNA
microarray analysis, we performed qRT-PCR assays for
some transcripts among those showing the largest
changes in gene expression (see in Table 1 ranking
genes down regulated in ATRX according to the ratio
ATRX/control). As shown in Figure 1 the putative lym-
phocyte G0/G1 switch (or G0S2) gene mRNA levels
(position 1 in Table 1), and the incyte EST clone ID
2820372, HAIK1 type I, intermediate filament cytocher-
atin or human Keratin 23 gene (KRT23, GeneID: 25984,
position 4 in Table 1) were decreased in the freshly
separated lymphomonocytes obtained by three different
ATRX patients confirming the cDNA microarray data.
On the contrary, the quantitative analysis in qRT-PCR
has not confirmed the strong reduction of oligophrenin-
1 (OPHN-1) mRNA (3.3 times lower in ATRX subjects)
observed by cDNA microarray (Figure 1A). However,
cDNA microarray data can be influenced by other tran-
scripts with a high level of homology. With this in
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homologs has been executed. Such analysis revealed the
presence of an “Oligophrenin-1-like (OPHN-1-L)” tran-
script deriving from the gene encoding for a previously
identified “RhoGAP” protein, called “GRAF1” (GTPase
regulator associated with the focal adhesion kinase
pp125FAK or Rho-type GTPase-activating protein 26)
[21]. The probe sequence in the microarray (Incyte
clone ID 4216520) covers part of the 5’ coding sequence
of the oligophrenin sequence which is 65% homologue
to GRAF1, a value that is enough to produce an
hybridization signal. Indeed, by quantitative RT-PCR
OPHN-1 mRNA levels in PBM were one order of mag-
nitude lower than GRAF1 levels, suggesting that the lat-
ter transcript was the major determinant of the
hybridization signal.
RNA from control subjects and ATRX patients was
examined by qRT-PCR analysis in order to evaluate the
level of GRAF1/OPHN-1-L transcript. These results
confirmed a reduction of the “GRAF1/OPHN-1-L” tran-
script levels with values equal to 41.64% (SEM 7.48) of
the controls in the three examined subjects (Figure 1A).
Table 1 List of the first 35 decreased transcripts revealed by cDNA microarray analysis (ratio ATRX/control < 0.5)
Gene name ratio ATRX/
control
GenBank ID Clone
ID
1 putative lymphocyte G0/G1 switch or G0S2 gene 0.23 BE873759 1217764
2 defensin, alpha 1, myeloid-related sequence 0.24 M26602 1716669
3 defensin, alpha 5, Paneth cell-specific 0.25 NM_021010 4174437
4 HAIK1 type I, intermediate filament cytocheratin or human Keratin 23 gene
(KRT23)
0.26 25984 2820372
5 tumor necrosis factor, alpha-induced protein 3 0.29 AI028304 1878791
6 Oligophrenin-1 (the signal is probably reflecting cross-hybridization to GRAF1/
OPHN-1-L, see text)
0.30 NM_002547 4216520
7 H.sapiens DNA for cyp related pseudogene 0.30 X90579 2073646
8 ESTs 0.31 AW470039 2136337
9 DKFZP434N093 protein 0.33 BG392388 1919233
10 XIAP associated factor-1 0.33 BG541762 4738521
11 immediate early response 3 0.36 N32077 1424495
12 Homo sapiens clone 24407 mRNA sequence 0.36 AF070575 488205
13 v-jun avian sarcoma virus 17 oncogene homolog 0.37 AI078377 1969563
14 small inducible cyt. Subfam. A (Cys-Cys), member 18, pulmonary and
activation-regulated
0.39 NM_002988 3473223
15 regulator of G-protein signalling 1 0.40 S59049 3120390
16 branched chain aminotransferase 1, cytosolic 0.39 AI970531 3290230
17 hypothetical protein FLJ23231 0.39 AA640102 2348706
18 small inducible cytokine subfamily B (Cys-X-Cys), member 10 0.39 NM_001565 1656473
19 lactotransferrin 0.42 M73700 1861911
20 B-cell CLL/lymphoma 3 0.43 NM_005178 1867294
21 polymerase (RNA) III (DNA directed) (39 kD) 0.43 XM_009639 1682994
22 HS (clone B3B3E13) chrom 4p16.3 DNA fragment 0.43 BE789464 2619
23 RAB6 interacting, kinesin-like (rabkinesin6) 0.43 AV714379 1975194
24 HS cDNA FLJ11918 fis, clone HEMBB1000272 0.44 AA810748 1921725
25 DEAD/H (Asp-Glu-Ala-Asp/His) box polyp. 21 0.45 U41387 1879532
26 dual specificity phosphatase 2 0.44 NM_004418 518826
27 hypothetical protein, expressed in osteoblast 0.44 F12860 2537863
28 hypothetical protein FLJ23306 0.48 AI088306 2372178
29 interleukin 8 0.48 AV717082 2785701
30 COX15 (yeast) homolog, cyt.c oxid. ass.protein 0.47 XM_005811 1976440
31 Incyte EST 0.49 2895226
32 hypoxia-ind. fact. 1, alpha sub (basic helix-loop-helix transcription factor) 0.48 AU134078 1711151
33 dihydrolipoamide branched chain transacylase (E2 comp of branched chain
keto acid dehyd. complex)
0.47 NM_001918 3521142
34 Human glucocorticoid receptor alpha mRNA, variant 3’ UTR 0.47 U25029 3127171
35 ATP/GTP-binding protein 0.48 AA188236 3032908
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in PBM cells we examined the GRAF1/OPHN-1-L
expression in immortalized lymphocyte lines of normal
and ATRX subjects. As it can be observed in Figure 1B
the GRAF1/OPHN-1-L mRNA levels were drastically
reduced in ATRX immortalized lines compared to
immortalized control cells. OPHN-1 mRNA levels were
not detectable in both ATRX and control cell lines (no
amplification to 40 cycles in 90% of the analyzed sam-
ples, data not shown).
Identification of a new splicing GRAF1/oligophrenin-1-like
transcript, variant-3
The search in the database, using as query sequence “oli-
gophrenin-1” (accession number NM_002547) supplied 2
sequences: the nucleotide sequence “GRAF1/OPHN-1-L,
variant-1"(deposited with accession number NM_015071)
and the nucleotide sequence “GRAF1/OPHN-1-L, var-
iant-2” (accession number NM_001135608).
The comparison of the two transcript isoforms of
“GRAF1/OPHN-1-L” sequences demonstrated that they
were two splicing variants of the same gene (Additional
file 2 Figure S1). The “GRAF1/OPHN-1-L” gene, loca-
lized on chromosome 5q31, is composed by 23 exons
and the complete translation produces a protein of 814
amino acids corresponding to the sequence deposited as
“GRAF1/OPHN-1-L, variant-1”.I nt h e“GRAF1/OPHN-
1-L, variant-2” is present only a 5’segment of exon 21,
while the “GRAF1/OPHN-1-L, variant-1” sequence con-
tains the whole exon 21. Therefore, the whole exon 21,
of 276 nucleotides, could be subdivided in two frag-
ments: the exon 21-I (from nucleotide position 2024 to
2134 in the sequence with accession number
NM_015071: 111 bases encoding a 37-amino acids
sequence) and the exon 21-II (from the nucleotide posi-
tion 2135 to 2299: 165 bases encoding a 55-amino acids
sequence). The transcript variant-1 contains the whole
exon 21 (exon21-I + exon21-II encoding a sequence of
92 amino acids; exon 21 is reported in NCBI GenBank
as exon 21b), while only exon 21-I (reported in NCBI
GenBank as exon 21a) is present in the transcript var-
iant-2 (Figure 2A, Table 3, Additional file 2 Figure S1).
The splicing of the exon 21-II does not modify the
reading frame, so that variant-2 differs from variant-1
only for the lack of 55 amino acids close to the carboxy-
terminal portion. Moreover the exon 21-II contains the
canonical splice acceptor and donor sites gt...ag in the
correct positions (Additional file 2 Figure S1). To inves-
tigate the presence of GRAF1/OPHN-1-L transcripts a
RT-PCR analysis was performed using specific primers
Table 2 List of the first 25 increased transcripts revealed by cDNA microarray analysis (ratio ATRX/control > 2)
Gene name ratio ATRX/control GenBank ID Clone ID
1 chemokine (C-X3-C) receptor 1 2.99 U20350 2305611
2 ESTs, Weakly sim to A48809 carboxylesterase [HS] 2.80 N44535 1877718
3 hemoglobin, beta 2.76 BG529867 3872557
4 granzyme B 2.69 M57888 1879670
5 hemoglobin, delta 2.66 NM_000519 133350
6 hemoglobin, gamma A 2.66 XM_006556 2156647
7 prostaglandin E receptor 4 2.62 NM_000958 1631793
8 nuclear receptor subfamily 1, group H, member 2 2.47 BE878950 2581075
9 VPS28 protein 2.37 BF663123 2355041
10 hypothetical protein FLJ23467 2.30 NM_024575 2632784
11 adenylyl cyclase-associated protein 2.17 BG286995 30672
12 selenophosphate synthetase 2 2.23 AW957160 1687542
13 granzyme A 2.16 AA283172 311922
14 CD8 antigen, alpha polypeptide (p32) 2.17 M12824 1846142
15 Fc fragment of IgE, high aff. I, rec for; alpha polyp. 2.18 BG542554 2762987
16 lamin B receptor 2.18 NM_002296 1803808
17 leukotriene A4 hydrolase 2.08 AI636026 1988019
18 Homo sapiens integrin, beta 1 2.08 BE880168 4089291
19 IQ motif containing GTPase activating protein 1 2.14 AI719158 1697314
20 CD3 D antigen, delta polypeptide (TiT3 complex) 2.11 AA310902 3297914
21 VPS28 protein 2.03 AF067420 2860815
22 Homo sapiens mRNA for single-chain antibody 1.97 AL560682 2237234
23 Homo sapiens clone 24775 mRNA sequence 1.99 AA402981 1671596
24 T cell receptor gamma locus 2.03 AI972955 1857652
25 vinculin 2.00 NM_014000 999864
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forward primers (F18, F19), localized to the exon 18 and
19, and two reverse primers (R22 and R22b), localized
to the exon 22, have been synthetized. RT-PCR amplifi-
cation with the primers F18 and R22b, generated 3
amplification bands of 724 bp, 559 bp, and 448 bp (Fig-
ure 2B). RT-PCR analysis, performed with the primers
F19 and R22 generated 3 amplification bands of 633 bp,
468 bp, and 357 bp (Figure 2C). The sequencing of the
amplification products revealed that the bands of greater
size (724 bp, 633 bp) contained the whole exon 21 (21-I
+ 21-II), the intermediate bands (559 bp, 468 bp) con-
tained only exon 21-I, while the band of smaller size
(448 bp, 357 bp) did not contain exon 21. Therefore,
besides the two known transcripts (variant-1 and var-
iant-2), one additional transcript variant (variant-3) was
detected in such analysis, suggesting that GRAF1/
OPHN-1-L gene generated three alternatively spliced
transcripts differing in the use of exon 21 (Additional
file 2 Figure S1). The translation of variant-3 sequence
Figure 1 Quantitative mRNA expression in ATRX patients. A. qRT-PCR analysis of the OPHN-1, GRAF1/OPHN-1-L, G0/G1 and HAIK1 transcript
levels in ATRX patients (n = 3, ATRX-1, ATRX-2, ATRX-3) and in normal controls (n = 8). Results are expressed as percentage of control average.
Each bar represents the mean ± SEM. Statistical significance was determined by Student t test and indicated by asterisks: * p < 0.05; ** p < 0.01.
B. qRT-PCR analysis showing a reduction of the GRAF1/OPHN-1-L transcript levels in the immortalized cell lines belonging to two ATRX patients,
ATRX-1, ATRX-2. Results are expressed as percentage of control average (n = 4 immortalized cell lines from normal subjects). Each column is the
average of three determination ± SD: * p < 0.01.
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variant-3 has been submitted to NCBI GenBank with
accession number HM037040.
Tissue distribution of “GRAF1/oligophrenin-1-like”
isoforms
GRAF1/OPHN-1-L expression was examined in specific
brain regions, as well as in a series of other adult tissues.
Figure 2C shows the tissue distribution of the GRAF1/
OPHN-1-L variants obtained using the forward primer
F19, localized to exon 19, and the reverse primers R22,
localized to exon 22. The GRAF1/OPHN-1-L variant-3
was predominantly and highly expressed in the human
cerebral areas (357 bp, Figure 2C). In the adult brain,
the transcript variant-3 was expressed in all tested
regions including cerebral cortex, hippocampus, medulla
oblongata, cerebellum, striatum, and spinal cord. In par-
enchymatous organs, endocrine glands, muscular tissue
and lymphomonocytes the variant-2 is predominant
( 4 6 8b p ,F i g u r e2 C ) .O nt h ec o n t r a r yt h ev a r i a n t - 1i s
weakly expressed in the cerebral tissues and in the per-
ipheral lymphocytes.
mRNA levels for alpha-and beta-globins in reticulocytes
Since alpha-thalassemia is one of the main feature of the
ATRX syndrome, changes in expression of the globin
Figure 2 Drawing and tissue distribution of GRAF1/OPHN-1-L isoforms. A. Schematic representation of the exon 20-to-22 of GRAF1/OPHN-
1-L variant-1 -2 and -3. Variant-1 contains the whole exon 21 reported in NCBI GenBank as exon 21b, variant-2 has exon 21-I (reported in NCBI
GenBank as exon 21a) while exclusion of exon 21 results in the variant-3. B. RT-PCR amplification of the GRAF1/OPHN-1-L transcripts (variant-1:
724 bp; variant-2: 559 bp; variant-3: 448 bp) was confirmed in neural e non neural tissues (Lm: lymphomonocytes, Cx: cerebral cortex, K: kidney)
with the other following primers: F18-R22b. C. Tissue distribution of GRAF1/OPHN-1-L isoforms. RT-PCR amplification of the GRAF1/OPHN-1-L
transcripts (variant-1: 633 bp; variant-2: 468 bp; variant-3: 357 bp) from various human organs and tissues with following primers: F19-R22. L: 100
bp ladder; Lm: lymphomonocytes, He: heart, Cx: cerebral cortex, S: spleen, SM: skeletal muscle, Li: liver, Lu: lung, K: kidney, T: testis, O: ovary, P:
pancreas, H: hippocampus, MO: medulla oblongata, Cb: cerebellum, St: striatum, SC: spinal cord.
Table 3 List of three GRAF1/OPHN-1-L isoforms: variant-1, variant-2 and variant-3.
Name Number of exons GenBank ID Exon number involved in splice site
(number of base involved)
Total number of aminoacids
GRAF1/OPHN-1-L, variant-1 23 NM_015071 Exon 21b
21-I + 21-II
(2024-2299)
276 nt
814
GRAF1/OPHN-1-L, variant-2 23 NM_001135608 Exon21a
21-I
(2024-2134)
111 nt
759
GRAF1/OPHN-1-L, variant-3 22 HM037040 No Exon 21 641
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chains were not present in the cDNA microarray plat-
form used for the present study, but we could detect
significant increases in the levels of the beta, gamma
and delta globin mRNAs in ATRX patients (values 2.76,
2.70, 2.66 times higher respectively, see Table 2). The
same analysis did not reveal significant differences for
the embryonic zeta-globin chains.
In order to confirm and to extend the cDNA microar-
ray results we performed a qRT-PCR analysis for the
alpha-and beta-globin transcripts. As reported in Figure
3 we found a reduction of the alpha/beta ratio (alpha
globin mRNA/beta globinm R N A )i nt w oA T R X
patients (ATRX-1 and ATRX-2) with values of 0.26 and
0.24 (controls mean = 1 ± 0.43; Figure 3), while ATRX-
3 had a value in the range of the controls (ATRX-3,
alpha/beta ratio 0.78). It is well-known that hematologic
findings vary widely among ATRX patients and in some
cases the manifestation of alpha-thalassemia may be
subtle [22]. Indeed, alpha/beta transcript ratios are in
agreement with the presence of erythrocyte HbH inclu-
sion bodies in ATRX-1 and ATRX-2 but not in ATRX-
3. The percentage of HbH cells to normal RBCs, visua-
lized by staining with 1% brilliant cresyl blue, were 1%,
3.7% and 0% in ATRX-1, ATRX-2 and ATRX-3,
respectively.
The presence of detectable globin transcripts in RNAs
extracted from lymphomonocyte samples suggested that
these cell preparations contained a nonnegligible
amount of contaminating reticulocytes. This hypothesis
is supported by the observation that such transcripts
showed a 3 times reduction in samples enriched for
CD4+ lymphocytes and by the fact they were not detect-
able in RNA samples extracted by immortalized lym-
phocyte cell lines. On this basis, we decided to perform
a quantitative analysis of alpha-and beta-globin tran-
scripts in RNA samples extracted from reticulocytes iso-
lated from the peripheral blood of control and ATRX
subjects. Indeed, such analysis confirmed the reduction
o ft h ea l p h a / b e t ar a t i oi nt h eA T R Xs u b j e c t s( F i g u r e4 ) .
However the absolute values of the alpha-and beta-glo-
bin transcripts showed remarkable variations between
samples and did not allow to establish if the modifica-
tion of the ratio is due to a decrease of alpha-globin
transcripts and/or an increase of beta-globin ones.
Discussion
It is well-known that one of the main clinical features of
the syndrome is the presence of a decreased expression
of alpha-globin genes leading to a form of alpha thalas-
semia. Indeed, qRT-PCR analysis confirmed a decrease
of the alpha-globin mRNA/beta-globin mRNA ratios, in
agreement with the known molecular alterations of the
disease. Moreover, the increase in beta-like chain gene
transcription, observed in microarray analysis, could be
considered a compensatory activity to alpha chain defi-
ciency. However much less is known about the mechan-
isms responsible for the other dominant clinical feature,
the mental retardation. Many lines of evidence support
a role for ATRX protein during cerebral development
and Berube et al. [23] proposed that transcription-
dependent events regulated by ATRX play a critical role
in mediating the survival of neurons in the developing
cortex and hippocampus. To date, although the ATRX
Figure 3 Alpha/beta ratio in ATRX lymphomonocytes.A l p h a -
globin/beta-globin mRNA ratio measured by qRT-PCR in
lymphomonocytes from the peripheral blood of patients, ATRX-1,
ATRX-2, ATRX-3 compared to control subjects (CTRLs).
Figure 4 Alpha/beta ratio in ATRX reticulocytes.q R T - P C R
analysis showing a reduction of alpha/beta ratio in reticulocytes
purified from the peripheral blood of patients (ATRX-1 and ATRX-2)
compared to control (pooled samples of six normal subjects). Data
are expressed as % of control and represent mean ± SD of two
independent experiments. Statistical significance was determined by
Student t test and indicated by asterisk: * p < 0.05.
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tion, it is not clear whether ATRX imparts predomi-
nantly a blocking or a positive effect on gene expression.
T h ec o m p l e x i t yo ft h es y n d r o m es u g g e s t st h a tA T R X
protein could be involved in the regulation of various
unidentified genes and the present work shows, indeed,
that altered expression in specific genes can be found in
this disease. As an exploratory tools to identify potential
candidate genes we used a cDNA array analysis, that
does not cover the entire range of cellular transcripts.
Indeed, such analysis suggested some specific transcripts
whose changes were confirmed by quantitative RT-PCR
analysis (a putative lymphocyte G0/G1 switch or G0S2
gene [24,25] and the human Keratin 23 gene, HAIK1
[26]. On the other hand, the gene expression change for
oligophrenin-1 was not confirmed by RT-PCR but drew
our attention on an homologous gene, the GRAF1/
OPHN-1-L gene, localized at chromosome 5q31 and
encoding for a Rho-GTPase-activating protein (Rho-
GAP). Indeed, GRAF1/OPHN-1-L expression is
decreased both in blood mononuclear cells and in
immortalized lymphoblastoid cells of ATRX patients.
Although, our analysis has been performed in peripheral
blood lymphomonocytes, it is interesting that the
GRAF1/OPHN-1-L transcript is highly expressed in the
human brain [27] and homologous to a gene, OPHN-1,
previously associated with X-linked mental retardation
[28]. GRAF1/OPHN-1-L protein contains a centrally
located GAP domain followed by a serine/proline-rich
domain and a carboxyl-terminal SH3 domain. The SH3
domain was shown to specifically bind to a proline-rich
region in the carboxy-terminus of FAK, protein-tyrosine
kinase associated with focal adhesions. Hildebrand et al.
[29] reported that, in vitro, GRAF1/OPHN-1-L has GAP
activity for Cdc42 and RhoA. Taylor et al. [27,30]
showed that GRAF1/OPHN-1-L specifically regulates
Rho activity in vivo, down-regulating Rho activity in
Swiss 3T3 cells but enhancing Rho-dependent effects in
PC12 cells. The latter cell line, used primarily as a neu-
ron model, has been established from a rat pheochro-
mocytoma, expressing high level of GRAF1/OPHN-1-L,
while Swiss 3T3 cells (or other fibroblast cell lines) did
not express detectable levels [30]. Moreover, GRAF1/
OPHN-1-L is enriched in the brain, where it could regu-
late Rho-mediated neurite retraction, and it has been
suggested that GRAF1/OPHN-1-L might play an impor-
tant role in neuronal cell morphology [27,30]. In parti-
cular GRAF1/OPHN-1-L should function as mediator
linking the extracellular guiding signals to the intracellu-
lar signal transduction pathways that are important for
neuronal morphogenesis as well as for cytoskeletal
dynamics within neuronal growth cones [27]. Alteration
of such pathways influencing growth and guidance of
axon outgrowth at neuronal growth cones might lead to
impaired formation of brain structures.
In the present paper, we report the tissue distribution
of a novel alternative splicing transcript (variant-3), lack-
ing the entire exon 21, and show that it represents the
main transcript in the brain. Exon 21 encodes for a por-
tion of GRAF1/OPHN-1-L protein (from aminoacid 664
to 755 in variant-1) localized between the serine/proline
rich domain (from aminoacid 584 to 701) and a car-
boxy-terminal Src-homology 3 (SH3) domain (from ami-
noacid 756 to 814). The three isoforms represent tissue-
specific alternative products. It is possible to suggest
that occurrence of exon 21 might be of importance to
regulate the distance between the serine/proline rich
domain and SH3 domain and the composition of the
serine/proline rich domain.
Another issue for future investigations is suggested by
the observation that somatic mutations of ATRX are
associated with alpha thalassaemia myelodysplastic syn-
drome, an acquired form of alpha-thalassaemia that most
commonly arises in the context of myelodysplasia
[31,32]. Taking into consideration that GRAF1/OPHN-1-
L inactivation has been detected in myelodysplasias and
leukemias [21,33], suggesting a role as tumor suppressor
for this gene, the link between inactivating mutations of
ATRX and decreased expression of GRAF1/OPHN-1-L,
observed in the present work, might explain the selection
of ATRX mutations in the course of leukemic progres-
sion. Analysis of GRAF1/OPHN-1-L expression and cor-
relation with ATRX activity deserves further studies in
such hematological malignancies.
Conclusion
O u rw o r ki d e n t i f i e ss o m eo ft h et r a n s c r i p t ss h o w i n g
altered expression in ATRX syndrome in peripheral
blood mononuclear cells and stimulates further studies
aimed to the direct measurements of such changes in
brain tissues of patients affected by this rare disease.
Moreover, these data provide the rationale for investiga-
tions aimed to analyse the possible involvement of
GRAF1/OPHN-1-L gene in other forms of mental
retardation.
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